EICHORPublic-registry site landscape for NCT03037645, “Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers”, a Chronic Lymphocytic Leukemia study sponsored by Sunesis Pharmaceuticals. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT03037645 (registry record) |
| Study title | Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers |
| Official title | A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study of the Noncovalent, Reversible Bruton's Tyrosine Kinase Inhibitor, SNS-062, in Patients With B-Lymphoid Malignancies |
| Sponsor | Sunesis Pharmaceuticals |
| Condition(s) | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Lymphoplasmacytoid Lymphoma; Mantle-Cell Lymphoma |
| Phase | PHASE1 / PHASE2 |
| Listed sites | 11 |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT03037645.
Eichor generates a preliminary site-risk snapshot for NCT03037645 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Chronic Lymphocytic Leukemia trials
← Eichor home · All tracked trials · Chronic Lymphocytic Leukemia studies · Weekly briefs
